The great news is that you won't have to do either. It's a new day coming.....oops, actually, it's already here. : )
There IS a risk from low hemoglobin caused by anemia. It makes the heart work harder pumping, since there is less oxygen being transported.
It can also be the fault of doctors who do not monitor the patients hemoglobin. I was anemic, but on the highest dose I just felt like I was working at a higher elevation. I never hit the low score which dictated mandatory stop/reduction of RBV.
It is also going to be a big change in riba consumption; most people will only need 12 weeks and also may be able to dose reduce.
I knew that the doctor could probably lower my RBV without risk so I requested it.
Another nice aspect of the newer drugs are that they often can be cut back, dosage reduced without impacting negatively on SVR rates. (this was also true for Incivek and Victrelis)
You will be amazed at the difference in treating now. You'll barely know you are on treatment.
I was TX naive, so I don't know the hell that you went through with your past TX. Some of it was just the extreme duration of the treatment.
Wishing you the best of luck on upcoming treatment. I don't have to wish you luck on the GILD investment; it is very close to a given that it will do well, and IMHO should do well for years.
~W
There IS a risk from low hemoglobin caused by anemia. It makes the heart work harder pumping, since there is less oxygen being transported.
It can also be the fault of doctors who do not monitor the patients hemoglobin. I was anemic, but on the highest dose I just felt like I was working at a higher elevation. I never hit the low score which dictated mandatory stop/reduction of RBV.
It is also going to be a big change in riba consumption; most people will only need 12 weeks and also may be able to dose reduce.
I knew that the doctor could probably lower my RBV without risk so I requested it.
Another nice aspect of the newer drugs are that they often can be cut back, dosage reduced without impacting negatively on SVR rates. (this was also true for Incivek and Victrelis)
You will be amazed at the difference in treating now. You'll barely know you are on treatment.
I was TX naive, so I don't know the hell that you went through with your past TX. Some of it was just the extreme duration of the treatment.
Wishing you the best of luck on upcoming treatment. I don't have to wish you luck on the GILD investment; it is very close to a given that it will do well, and IMHO should do well for years.
~W
Recent GILD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 12:55:23 AM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 05/28/2026 12:51:00 AM
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar) • Business Wire • 05/27/2026 06:00:00 AM
- FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) • Business Wire • 05/22/2026 06:00:00 PM
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors • Business Wire • 05/22/2026 11:47:00 AM
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology • Business Wire • 05/21/2026 09:00:00 PM
- Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio • Business Wire • 05/21/2026 01:30:00 PM
- Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease • Business Wire • 05/21/2026 07:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:15:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:50:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:45:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 08:15:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:09:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:07:18 PM
- Gilead Prices $3 Billion of Senior Unsecured Notes • Business Wire • 05/15/2026 01:21:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/14/2026 09:11:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/14/2026 12:46:00 PM
- Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 • Business Wire • 05/13/2026 12:30:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/08/2026 09:00:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 09:13:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 09:12:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:03:01 PM
- Gilead Sciences Announces First Quarter Financial Results • Business Wire • 05/07/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:40:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:36:45 PM
